7cak › Citations

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody.

Lv Z, Deng YQ, Ye Q, Cao L, Sun CY, Fan C, Huang W, Sun S, Sun Y, Zhu L, Chen Q, Wang N, Nie J, Cui Z, Zhu D, Shaw N, Li XF, Li Q, Xie L, Wang Y, Rao Z, Qin CF, Wang X
Science 369 1505-1509 (2020)
Related entries: 7cab, 7cac, 7cah, 7cai

Cited: 249 times
EuropePMC logo PMID: 32703908

Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. There are no approved vaccines or therapeutics for treating COVID-19. Here we report a humanized monoclonal antibody, H014, that efficiently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 at nanomolar concentrations by engaging the spike (S) receptor binding domain (RBD). H014 administration reduced SARS-CoV-2 titers in infected lungs and prevented pulmonary pathology in a human angiotensin-converting enzyme 2 mouse model. Cryo-electron microscopy characterization of the SARS-CoV-2 S trimer in complex with the H014 Fab fragment unveiled a previously uncharacterized conformational epitope, which was only accessible when the RBD was in an open conformation. Biochemical, cellular, virological, and structural studies demonstrated that H014 prevents attachment of SARS-CoV-2 to its host cell receptors. Epitope analysis of available neutralizing antibodies against SARS-CoV and SARS-CoV-2 uncovered broad cross-protective epitopes. Our results highlight a key role for antibody-based therapeutic interventions in the treatment of COVID-19.

Reviews - 7cak mentioned but not cited (2)

  1. Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment. Valdez-Cruz NA, García-Hernández E, Espitia C, Cobos-Marín L, Altamirano C, Bando-Campos CG, Cofas-Vargas LF, Coronado-Aceves EW, González-Hernández RA, Hernández-Peralta P, Juárez-López D, Ortega-Portilla PA, Restrepo-Pineda S, Zelada-Cordero P, Trujillo-Roldán MA. Microb Cell Fact 20 88 (2021)
  2. Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants. Ghimire D, Han Y, Lu M. Viruses 14 1255 (2022)

Articles - 7cak mentioned but not cited (19)

  1. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Dong J, Zost SJ, Greaney AJ, Starr TN, Dingens AS, Chen EC, Chen RE, Case JB, Sutton RE, Gilchuk P, Rodriguez J, Armstrong E, Gainza C, Nargi RS, Binshtein E, Xie X, Zhang X, Shi PY, Logue J, Weston S, McGrath ME, Frieman MB, Brady T, Tuffy KM, Bright H, Loo YM, McTamney PM, Esser MT, Carnahan RH, Diamond MS, Bloom JD, Crowe JE. Nat Microbiol 6 1233-1244 (2021)
  2. Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. Jette CA, Cohen AA, Gnanapragasam PNP, Muecksch F, Lee YE, Huey-Tubman KE, Schmidt F, Hatziioannou T, Bieniasz PD, Nussenzweig MC, West AP, Keeffe JR, Bjorkman PJ, Barnes CO. Cell Rep 36 109760 (2021)
  3. Integrated Biophysical Modeling of the SARS-CoV-2 Spike Protein Binding and Allosteric Interactions with Antibodies. Verkhivker GM, Di Paola L. J Phys Chem B 125 4596-4619 (2021)
  4. A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro. Cheng MH, Porritt RA, Rivas MN, Krieger JM, Ozdemir AB, Garcia G, Arumugaswami V, Fries BC, Arditi M, Bahar I. Structure 29 951-962.e3 (2021)
  5. Spike-Dependent Opsonization Indicates Both Dose-Dependent Inhibition of Phagocytosis and That Non-Neutralizing Antibodies Can Confer Protection to SARS-CoV-2. Bahnan W, Wrighton S, Sundwall M, Bläckberg A, Larsson O, Höglund U, Khakzad H, Godzwon M, Walle M, Elder E, Strand AS, Happonen L, André O, Ahnlide JK, Hellmark T, Wendel-Hansen V, Wallin RP, Malmstöm J, Malmström L, Ohlin M, Rasmussen M, Nordenfelt P. Front Immunol 12 808932 (2021)
  6. Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes. Fu D, Zhang G, Wang Y, Zhang Z, Hu H, Shen S, Wu J, Li B, Li X, Fang Y, Liu J, Wang Q, Zhou Y, Wang W, Li Y, Lu Z, Wang X, Nie C, Tian Y, Chen D, Wang Y, Zhou X, Wang Q, Yu F, Zhang C, Deng C, Zhou L, Guan G, Shao N, Lou Z, Deng F, Zhang H, Chen X, Wang M, Liu L, Rao Z, Guo Y. PLoS Biol 19 e3001209 (2021)
  7. Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies. Stefan MA, Light YK, Schwedler JL, McIlroy PR, Courtney CM, Saada EA, Thatcher CE, Phillips AM, Bourguet FA, Mageeney CM, McCloy SA, Collette NM, Negrete OA, Schoeniger JS, Weilhammer DR, Harmon B. MAbs 13 1958663 (2021)
  8. Elucidating important structural features for the binding affinity of spike - SARS-CoV-2 neutralizing antibody complexes. Sharma D, Rawat P, Janakiraman V, Gromiha MM. Proteins 90 824-834 (2022)
  9. Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2. Huang KA, Chen X, Mohapatra A, Nguyen HTV, Schimanski L, Tan TK, Rijal P, Vester SK, Hills RA, Howarth M, Keeffe JR, Cohen AA, Kakutani LM, Wu YM, Shahed-Al-Mahmud M, Chou YC, Bjorkman PJ, Townsend AR, Ma C. Nat Commun 14 311 (2023)
  10. research-article A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro. Cheng MH, Porritt RA, Rivas MN, Krieger JM, Ozdemir AB, Garcia G, Arumugaswami V, Fries BC, Arditi M, Bahar I. bioRxiv 2020.11.24.395079 (2020)
  11. research-article Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. Jette CA, Cohen AA, Gnanapragasam PNP, Muecksch F, Lee YE, Huey-Tubman KE, Schmidt F, Hatziioannou T, Bieniasz PD, Nussenzweig MC, West AP, Keeffe JR, Bjorkman PJ, Barnes CO. bioRxiv 2021.04.23.441195 (2021)
  12. Impact of new variants on SARS-CoV-2 infectivity and neutralization: A molecular assessment of the alterations in the spike-host protein interactions. Cheng MH, Krieger JM, Banerjee A, Xiang Y, Kaynak B, Shi Y, Arditi M, Bahar I. iScience 25 103939 (2022)
  13. Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview. Mehra R, Kepp KP. ACS Infect Dis 8 29-58 (2022)
  14. Analysis of the Neutralizing Activity of Antibodies Targeting Open or Closed SARS-CoV-2 Spike Protein Conformations. Cia G, Pucci F, Rooman M. Int J Mol Sci 23 2078 (2022)
  15. Comprehensive structural analysis reveals broad-spectrum neutralizing antibodies against SARS-CoV-2 Omicron variants. Chi X, Xia L, Zhang G, Chi X, Huang B, Zhang Y, Chen Z, Han J, Wu L, Li Z, Sun H, Huang P, Yu C, Chen W, Zhou Q. Cell Discov 9 37 (2023)
  16. Computational epitope mapping of class I fusion proteins using low complexity supervised learning methods. Fischer MFS, Crowe JE, Meiler J. PLoS Comput Biol 18 e1010230 (2022)
  17. Receptor-binding domain-anchored peptides block binding of severe acute respiratory syndrome coronavirus 2 spike proteins with cell surface angiotensin-converting enzyme 2. Wang T, Xu J, Wang B, Wang Y, Zhao W, Xiang B, Xue Y, Yuan Q, Wang Y. Front Microbiol 13 910343 (2022)
  18. research-article Structural models of SARS-CoV-2 Omicron variant in complex with ACE2 receptor or antibodies suggest altered binding interfaces. Lubin JH, Markosian C, Balamurugan D, Pasqualini R, Arap W, Burley SK, Khare SD. bioRxiv 2021.12.12.472313 (2021)
  19. Superimmunity by pan-sarbecovirus nanobodies. Xiang Y, Huang W, Liu H, Sang Z, Nambulli S, Tubiana J, Williams KL, Duprex WP, Schneidman-Duhovny D, Wilson IA, Taylor DJ, Shi Y. Cell Rep 39 111004 (2022)


Reviews citing this publication (82)

  1. The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens. Duan L, Zheng Q, Zhang H, Niu Y, Lou Y, Wang H. Front Immunol 11 576622 (2020)
  2. Mechanisms of SARS-CoV-2 entry into cells. Jackson CB, Farzan M, Chen B, Choe H. Nat Rev Mol Cell Biol 23 3-20 (2022)
  3. COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19. Yang L, Liu W, Yu X, Wu M, Reichert JM, Ho M. Antib Ther 3 205-212 (2020)
  4. Viral Emerging Diseases: Challenges in Developing Vaccination Strategies. Trovato M, Sartorius R, D'Apice L, Manco R, De Berardinis P. Front Immunol 11 2130 (2020)
  5. Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Zhang Q, Xiang R, Huo S, Zhou Y, Jiang S, Wang Q, Yu F. Signal Transduct Target Ther 6 233 (2021)
  6. Antibodies and Vaccines Target RBD of SARS-CoV-2. Min L, Sun Q. Front Mol Biosci 8 671633 (2021)
  7. Cell entry by SARS-CoV-2. Peng R, Wu LA, Wang Q, Qi J, Gao GF. Trends Biochem Sci 46 848-860 (2021)
  8. A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain. Niu L, Wittrock KN, Clabaugh GC, Srivastava V, Cho MW. Front Immunol 12 647934 (2021)
  9. Structural biology of SARS-CoV-2 and implications for therapeutic development. Yang H, Rao Z. Nat Rev Microbiol 19 685-700 (2021)
  10. Animal models for SARS-CoV-2. Lee CY, Lowen AC. Curr Opin Virol 48 73-81 (2021)
  11. Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination. Altawalah H. Vaccines (Basel) 9 910 (2021)
  12. Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective. Huang Y, Sun H, Yu H, Li S, Zheng Q, Xia N. Antib Ther 3 285-299 (2020)
  13. Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2. Renn A, Fu Y, Hu X, Hall MD, Simeonov A. Trends Pharmacol Sci 41 815-829 (2020)
  14. Microarray patches enable the development of skin-targeted vaccines against COVID-19. Korkmaz E, Balmert SC, Sumpter TL, Carey CD, Erdos G, Falo LD. Adv Drug Deliv Rev 171 164-186 (2021)
  15. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. Pang NY, Pang AS, Chow VT, Wang DY. Mil Med Res 8 47 (2021)
  16. COVID-19 mRNA vaccines. Huang Q, Zeng J, Yan J. J Genet Genomics 48 107-114 (2021)
  17. The Mechanisms and Animal Models of SARS-CoV-2 Infection. Jia W, Wang J, Sun B, Zhou J, Shi Y, Zhou Z. Front Cell Dev Biol 9 578825 (2021)
  18. The humoral response and antibodies against SARS-CoV-2 infection. Qi H, Liu B, Wang X, Zhang L. Nat Immunol 23 1008-1020 (2022)
  19. Microfluidics Technology in SARS-CoV-2 Diagnosis and Beyond: A Systematic Review. Jamiruddin MR, Meghla BA, Islam DZ, Tisha TA, Khandker SS, Khondoker MU, Haq MA, Adnan N, Haque M. Life (Basel) 12 649 (2022)
  20. The development of neutralizing antibodies against SARS-CoV-2 and their common features. Liu LD, Lian C, Yeap LS, Meng FL. J Mol Cell Biol 12 980-986 (2020)
  21. Therapeutic Potential of Exploiting Autophagy Cascade Against Coronavirus Infection. Maity S, Saha A. Front Microbiol 12 675419 (2021)
  22. Development and application of therapeutic antibodies against COVID-19. Ning L, Abagna HB, Jiang Q, Liu S, Huang J. Int J Biol Sci 17 1486-1496 (2021)
  23. The role and uses of antibodies in COVID-19 infections: a living review. Scourfield DO, Reed SG, Quastel M, Alderson J, Bart VMT, Teijeira Crespo A, Jones R, Pring E, Richter FC, Oxford-Cardiff COVID-19 Literature Consortium , Burnell SEA. Oxf Open Immunol 2 iqab003 (2021)
  24. Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. Mengist HM, Kombe Kombe AJ, Mekonnen D, Abebaw A, Getachew M, Jin T. Semin Immunol 55 101533 (2021)
  25. Association of COVID-19 transmission with high levels of ambient pollutants: Initiation and impact of the inflammatory response on cardiopulmonary disease. Lai A, Chang ML, O'Donnell RP, Zhou C, Sumner JA, Hsiai TK. Sci Total Environ 779 146464 (2021)
  26. Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants. Shrestha LB, Tedla N, Bull RA. Front Immunol 12 752003 (2021)
  27. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. Hwang YC, Lu RM, Su SC, Chiang PY, Ko SH, Ke FY, Liang KH, Hsieh TY, Wu HC. J Biomed Sci 29 1 (2022)
  28. Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2. Baral PK, Yin J, James MNG. Int J Biol Macromol 186 490-500 (2021)
  29. Endocytosis and Transcytosis of SARS-CoV-2 Across the Intestinal Epithelium and Other Tissue Barriers. Knyazev E, Nersisyan S, Tonevitsky A. Front Immunol 12 636966 (2021)
  30. Prospects of Neutralizing Nanobodies Against SARS-CoV-2. Chen F, Liu Z, Jiang F. Front Immunol 12 690742 (2021)
  31. Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant. Zhou H, Møhlenberg M, Thakor JC, Tuli HS, Wang P, Assaraf YG, Dhama K, Jiang S. Clin Microbiol Rev 35 e0001422 (2022)
  32. Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions. Gavor E, Choong YK, Er SY, Sivaraman H, Sivaraman J. Trends Immunol 41 1006-1022 (2020)
  33. Structural insights into SARS-CoV-2 infection and therapeutics development. Sun G, Xue L, He Q, Zhao Y, Xu W, Wang Z. Stem Cell Res 52 102219 (2021)
  34. Advanced microscopy technologies enable rapid response to SARS-CoV-2 pandemic. Cortese M, Laketa V. Cell Microbiol 23 e13319 (2021)
  35. Antibodies at work in the time of severe acute respiratory syndrome coronavirus 2. Sajna KV, Kamat S. Cytotherapy 23 101-110 (2021)
  36. Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies. Ling Z, Yi C, Sun X, Yang Z, Sun B. Sci China Life Sci 66 658-678 (2023)
  37. Epitope mapping of neutralising anti-SARS-CoV-2 monoclonal antibodies: Implications for immunotherapy and vaccine design. Ghotloo S, Maghsood F, Golsaz-Shirazi F, Amiri MM, Moog C, Shokri F. Rev Med Virol 32 e2347 (2022)
  38. Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology. Zhuo LS, Wang MS, Yang JF, Xu HC, Huang W, Shang LQ, Yang GF. Top Curr Chem (Cham) 379 23 (2021)
  39. Monoclonal Antibodies against SARS-CoV-2: Current Scenario and Future Perspectives. Quiros-Roldan E, Amadasi S, Zanella I, Degli Antoni M, Storti S, Tiecco G, Castelli F. Pharmaceuticals (Basel) 14 1272 (2021)
  40. Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection. Kombe Kombe AJ, Zahid A, Mohammed A, Shi R, Jin T. Front Mol Biosci 8 670815 (2021)
  41. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. Yu F, Xiang R, Deng X, Wang L, Yu Z, Tian S, Liang R, Li Y, Ying T, Jiang S. Signal Transduct Target Ther 5 212 (2020)
  42. SARS-CoV-2: Origin, Evolution, and Targeting Inhibition. Ning S, Yu B, Wang Y, Wang F. Front Cell Infect Microbiol 11 676451 (2021)
  43. Single-cell analysis of the adaptive immune response to SARS-CoV-2 infection and vaccination. Qi F, Cao Y, Zhang S, Zhang Z. Front Immunol 13 964976 (2022)
  44. Antibody-mediated immunity to SARS-CoV-2 spike. Errico JM, Adams LJ, Fremont DH. Adv Immunol 154 1-69 (2022)
  45. Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China. Yang L, Wang Z. Eur J Med Chem 257 115503 (2023)
  46. Could live attenuated vaccines better control COVID-19? Okamura S, Ebina H. Vaccine 39 5719-5726 (2021)
  47. How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika. Abernathy ME, Dam KA, Esswein SR, Jette CA, Bjorkman PJ. Viruses 13 2106 (2021)
  48. Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy. Zhou D, Zhou R, Chen Z. Immunother Adv 2 ltab027 (2022)
  49. Monoclonal antibodies: a remedial approach to prevent SARS-CoV-2 infection. Kumar S, Dutta D, Ravichandiran V, Sukla S. 3 Biotech 12 227 (2022)
  50. Protective neutralizing epitopes in SARS-CoV-2. Liu H, Wilson IA. Immunol Rev 310 76-92 (2022)
  51. Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era. Pecetta S, Finco O, Seubert A. Semin Immunol 50 101427 (2020)
  52. Update on Extracellular Vesicle-Based Vaccines and Therapeutics to Combat COVID-19. Mustajab T, Kwamboka MS, Choi DA, Kang DW, Kim J, Han KR, Han Y, Lee S, Song D, Chwae YJ. Int J Mol Sci 23 11247 (2022)
  53. A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease. Wu Y, Song H. Life (Basel) 12 130 (2022)
  54. A structural view of the SARS-CoV-2 virus and its assembly. Hardenbrook NJ, Zhang P. Curr Opin Virol 52 123-134 (2022)
  55. An overview of methods for the structural and functional mapping of epitopes recognized by anti-SARS-CoV-2 antibodies. Francino-Urdaniz IM, Whitehead TA. RSC Chem Biol 2 1580-1589 (2021)
  56. An unexpected biomaterial against SARS-CoV-2: Bio-polyphosphate blocks binding of the viral spike to the cell receptor. Müller WEG, Schröder HC, Neufurth M, Wang X. Mater Today (Kidlington) 51 504-524 (2021)
  57. Analysis of the molecular mechanism of SARS-CoV-2 antibodies. Jin D, Wei J, Sun J. Biochem Biophys Res Commun 566 45-52 (2021)
  58. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development? Lu L, Zhang H, Zhan M, Jiang J, Yin H, Dauphars DJ, Li SY, Li Y, He YW. Sci China Life Sci 63 1833-1849 (2020)
  59. Application of Baculovirus Expression Vector system (BEV) for COVID-19 diagnostics and therapeutics: a review. Azali MA, Mohamed S, Harun A, Hussain FA, Shamsuddin S, Johan MF. J Genet Eng Biotechnol 20 98 (2022)
  60. Applications of nanobodies in the prevention, detection, and treatment of the evolving SARS-CoV-2. Wang W, Hu Y, Li B, Wang H, Shen J. Biochem Pharmacol 208 115401 (2023)
  61. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Chen Y, Zhao X, Zhou H, Zhu H, Jiang S, Wang P. Nat Rev Immunol (2022)
  62. Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy. Cruz-Teran C, Tiruthani K, McSweeney M, Ma A, Pickles R, Lai SK. Adv Drug Deliv Rev 169 100-117 (2021)
  63. Clinical Application of Antibody Immunity Against SARS-CoV-2: Comprehensive Review on Immunoassay and Immunotherapy. Cheng ZJ, Li B, Zhan Z, Zhao Z, Xue M, Zheng P, Lyu J, Hu C, He J, Chen R, Sun B. Clin Rev Allergy Immunol (2022)
  64. Engineering viral genomics and nano-liposomes in microfluidic platforms for patient-specific analysis of SARS-CoV-2 variants. Satta S, Shahabipour F, Gao W, Lentz SR, Perlman S, Ashammakhi N, Hsiai T. Theranostics 12 4779-4790 (2022)
  65. Epitope Analysis of Anti-SARS-CoV-2 Neutralizing Antibodies. Xue JB, Tao SC. Curr Med Sci 41 1065-1074 (2021)
  66. Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CLpro and PLpro), spike protein, RNA-dependent RNA polymerase (RdRp) and angiotensin-converting enzyme II receptor (ACE2). Mouffouk C, Mouffouk S, Mouffouk S, Hambaba L, Haba H. Eur J Pharmacol 891 173759 (2021)
  67. Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19. Chen J, Huang R, Nie Y, Wen X, Wu Y. Virol Sin 35 713-724 (2020)
  68. Immunopathology, host-virus genome interactions, and effective vaccine development in SARS-CoV-2. Singh DD, Han I, Choi EH, Yadav DK. Comput Struct Biotechnol J 18 3774-3787 (2020)
  69. Multi-omics for COVID-19: driving development of therapeutics and vaccines. Guo M, Xiong M, Peng J, Guan T, Su H, Huang Y, Yang CG, Li Y, Boraschi D, Pillaiyar T, Wang G, Yi C, Xu Y, Chen C. Natl Sci Rev 10 nwad161 (2023)
  70. Native, engineered and de novo designed ligands targeting the SARS-CoV-2 spike protein. Costa CFS, Barbosa AJM, Dias AMGC, Roque ACA. Biotechnol Adv 59 107986 (2022)
  71. Neutralizing monoclonal antibodies against highly pathogenic coronaviruses. Xiang R, Wang Y, Wang L, Deng X, Huo S, Jiang S, Yu F. Curr Opin Virol 53 101199 (2022)
  72. Neutralizing monoclonal antibodies for COVID-19 treatment and prevention. Jaworski JP. Biomed J (2020)
  73. Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. Strohl WR, Ku Z, An Z, Carroll SF, Keyt BA, Strohl LM. BioDrugs 36 231-323 (2022)
  74. Progress in the Development of Structure-Based Vaccines. Thomas S, Abraham A. Methods Mol Biol 2412 15-33 (2022)
  75. SARS-CoV-2-Specific Vaccine Candidates; the Contribution of Structural Vaccinology. Pack SM, Peters PJ. Vaccines (Basel) 10 236 (2022)
  76. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies. Finkelstein MT, Mermelstein AG, Parker Miller E, Seth PC, Stancofski ED, Fera D. Viruses 13 (2021)
  77. Structural Requirements and Plasticity of Receptor-Binding Domain in Human Coronavirus Spike. Li Y, Zheng P, Liu T, Shi C, Wang B, Xu Y, Jin T. Front Mol Biosci 9 930931 (2022)
  78. Structural and Computational Studies of the SARS-CoV-2 Spike Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-Driven Nanobody Engineering. Verkhivker G. Int J Mol Sci 23 2928 (2022)
  79. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants. Mittal A, Khattri A, Verma V. PLoS Pathog 18 e1010260 (2022)
  80. Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies. Huang Q, Han X, Yan J. Emerg Microbes Infect 11 2412-2422 (2022)
  81. Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak. Maciorowski D, Ogaugwu C, Durvasula SR, Durvasula R, Kunamneni A. SLAS Discov 26 311-329 (2021)
  82. Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming? Zhang J, Zhang H, Sun L. MAbs 14 2031483 (2022)

Articles citing this publication (146)

  1. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cerutti G, Guo Y, Zhou T, Gorman J, Lee M, Rapp M, Reddem ER, Yu J, Bahna F, Bimela J, Huang Y, Katsamba PS, Liu L, Nair MS, Rawi R, Olia AS, Wang P, Zhang B, Chuang GY, Ho DD, Sheng Z, Kwong PD, Shapiro L. Cell Host Microbe 29 819-833.e7 (2021)
  2. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Li Q, Nie J, Wu J, Zhang L, Ding R, Wang H, Zhang Y, Li T, Liu S, Zhang M, Zhao C, Liu H, Nie L, Qin H, Wang M, Lu Q, Li X, Liu J, Liang H, Shi Y, Shen Y, Xie L, Zhang L, Qu X, Xu W, Huang W, Wang Y. Cell 184 2362-2371.e9 (2021)
  3. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. Koenig PA, Das H, Liu H, Kümmerer BM, Gohr FN, Jenster LM, Schiffelers LDJ, Tesfamariam YM, Uchima M, Wuerth JD, Gatterdam K, Ruetalo N, Christensen MH, Fandrey CI, Normann S, Tödtmann JMP, Pritzl S, Hanke L, Boos J, Yuan M, Zhu X, Schmid-Burgk JL, Kato H, Schindler M, Wilson IA, Geyer M, Ludwig KU, Hällberg BM, Wu NC, Schmidt FI. Science 371 eabe6230 (2021)
  4. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Huang W, Li Q, Wang P, An R, Wang J, Wang Y, Niu X, Yang S, Liang H, Sun H, Li T, Yu Y, Cui Q, Liu S, Yang X, Du S, Zhang Z, Hao X, Shao F, Jin R, Wang X, Xiao J, Wang Y, Xie XS. Nature 602 657-663 (2022)
  5. The antigenic anatomy of SARS-CoV-2 receptor binding domain. Dejnirattisai W, Zhou D, Ginn HM, Duyvesteyn HME, Supasa P, Case JB, Zhao Y, Walter TS, Mentzer AJ, Liu C, Wang B, Paesen GC, Slon-Campos J, López-Camacho C, Kafai NM, Bailey AL, Chen RE, Ying B, Thompson C, Bolton J, Fyfe A, Gupta S, Tan TK, Gilbert-Jaramillo J, James W, Knight M, Carroll MW, Skelly D, Dold C, Peng Y, Levin R, Dong T, Pollard AJ, Knight JC, Klenerman P, Temperton N, Hall DR, Williams MA, Paterson NG, Bertram FKR, Siebert CA, Clare DK, Howe A, Radecke J, Song Y, Townsend AR, Huang KA, Fry EE, Mongkolsapaya J, Diamond MS, Ren J, Stuart DI, Screaton GR. Cell 184 2183-2200.e22 (2021)
  6. The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, Zhao C, Zhang Q, Liu H, Nie L, Qin H, Wang M, Lu Q, Li X, Sun Q, Liu J, Zhang L, Li X, Huang W, Wang Y. Cell 182 1284-1294.e9 (2020)
  7. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Zhao MM, Yang WL, Yang FY, Zhang L, Huang WJ, Hou W, Fan CF, Jin RH, Feng YM, Wang YC, Yang JK. Signal Transduct Target Ther 6 134 (2021)
  8. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. Liu Y, Soh WT, Kishikawa JI, Hirose M, Nakayama EE, Li S, Sasai M, Suzuki T, Tada A, Arakawa A, Matsuoka S, Akamatsu K, Matsuda M, Ono C, Torii S, Kishida K, Jin H, Nakai W, Arase N, Nakagawa A, Matsumoto M, Nakazaki Y, Shindo Y, Kohyama M, Tomii K, Ohmura K, Ohshima S, Okamoto T, Yamamoto M, Nakagami H, Matsuura Y, Nakagawa A, Kato T, Okada M, Standley DM, Shioda T, Arase H. Cell 184 3452-3466.e18 (2021)
  9. Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area. Long SW, Olsen RJ, Christensen PA, Bernard DW, Davis JJ, Shukla M, Nguyen M, Saavedra MO, Yerramilli P, Pruitt L, Subedi S, Kuo HC, Hendrickson H, Eskandari G, Nguyen HAT, Long JH, Kumaraswami M, Goike J, Boutz D, Gollihar J, McLellan JS, Chou CW, Javanmardi K, Finkelstein IJ, Musser JM. mBio 11 e02707-20 (2020)
  10. Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans. Vanshylla K, Di Cristanziano V, Kleipass F, Dewald F, Schommers P, Gieselmann L, Gruell H, Schlotz M, Ercanoglu MS, Stumpf R, Mayer P, Zehner M, Heger E, Johannis W, Horn C, Suárez I, Jung N, Salomon S, Eberhardt KA, Gathof B, Fätkenheuer G, Pfeifer N, Eggeling R, Augustin M, Lehmann C, Klein F. Cell Host Microbe 29 917-929.e4 (2021)
  11. Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients. Li Y, Ma ML, Lei Q, Wang F, Hong W, Lai DY, Hou H, Xu ZW, Zhang B, Chen H, Yu C, Xue JB, Zheng YX, Wang XN, Jiang HW, Zhang HN, Qi H, Guo SJ, Zhang Y, Lin X, Yao Z, Wu J, Sheng H, Zhang Y, Wei H, Sun Z, Fan X, Tao SC. Cell Rep 34 108915 (2021)
  12. A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies. Wang C, van Haperen R, Gutiérrez-Álvarez J, Li W, Okba NMA, Albulescu I, Widjaja I, van Dieren B, Fernandez-Delgado R, Sola I, Hurdiss DL, Daramola O, Grosveld F, van Kuppeveld FJM, Haagmans BL, Enjuanes L, Drabek D, Bosch BJ. Nat Commun 12 1715 (2021)
  13. Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies. Cerutti G, Rapp M, Guo Y, Bahna F, Bimela J, Reddem ER, Yu J, Wang P, Liu L, Huang Y, Ho DD, Kwong PD, Sheng Z, Shapiro L. Structure 29 655-663.e4 (2021)
  14. Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class. Rapp M, Guo Y, Reddem ER, Yu J, Liu L, Wang P, Cerutti G, Katsamba P, Bimela JS, Bahna FA, Mannepalli SM, Zhang B, Kwong PD, Huang Y, Ho DD, Shapiro L, Sheng Z. Cell Rep 35 108950 (2021)
  15. Prediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapies. Chen J, Gao K, Wang R, Wei GW. Chem Sci 12 6929-6948 (2021)
  16. Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. Nabel KG, Clark SA, Shankar S, Pan J, Clark LE, Yang P, Coscia A, McKay LGA, Varnum HH, Brusic V, Tolan NV, Zhou G, Desjardins M, Turbett SE, Kanjilal S, Sherman AC, Dighe A, LaRocque RC, Ryan ET, Tylek C, Cohen-Solal JF, Darcy AT, Tavella D, Clabbers A, Fan Y, Griffiths A, Correia IR, Seagal J, Baden LR, Charles RC, Abraham J. Science 375 eabl6251 (2022)
  17. Computational epitope map of SARS-CoV-2 spike protein. Sikora M, von Bülow S, Blanc FEC, Gecht M, Covino R, Hummer G. PLoS Comput Biol 17 e1008790 (2021)
  18. A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. Wu NC, Yuan M, Bangaru S, Huang D, Zhu X, Lee CD, Turner HL, Peng L, Yang L, Burton DR, Nemazee D, Ward AB, Wilson IA. PLoS Pathog 16 e1009089 (2020)
  19. An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models. Schepens B, van Schie L, Nerinckx W, Roose K, Van Breedam W, Fijalkowska D, Devos S, Weyts W, De Cae S, Vanmarcke S, Lonigro C, Eeckhaut H, Van Herpe D, Borloo J, Oliveira AF, Catani JPP, Creytens S, De Vlieger D, Michielsen G, Marchan JCZ, Moschonas GD, Rossey I, Sedeyn K, Van Hecke A, Zhang X, Langendries L, Jacobs S, Ter Horst S, Seldeslachts L, Liesenborghs L, Boudewijns R, Thibaut HJ, Dallmeier K, Velde GV, Weynand B, Beer J, Schnepf D, Ohnemus A, Remory I, Foo CS, Abdelnabi R, Maes P, Kaptein SJF, Rocha-Pereira J, Jochmans D, Delang L, Peelman F, Staeheli P, Schwemmle M, Devoogdt N, Tersago D, Germani M, Heads J, Henry A, Popplewell A, Ellis M, Brady K, Turner A, Dombrecht B, Stortelers C, Neyts J, Callewaert N, Saelens X. Sci Transl Med 13 eabi7826 (2021)
  20. Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2. Sun X, Yi C, Zhu Y, Ding L, Xia S, Chen X, Liu M, Gu C, Lu X, Fu Y, Chen S, Zhang T, Zhang Y, Yang Z, Ma L, Gu W, Hu G, Du S, Yan R, Fu W, Yuan S, Qiu C, Zhao C, Zhang X, He Y, Qu A, Zhou X, Li X, Wong G, Deng Q, Zhou Q, Lu H, Ling Z, Ding J, Lu L, Xu J, Xie Y, Sun B. Nat Microbiol 7 1063-1074 (2022)
  21. B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. Scheid JF, Barnes CO, Eraslan B, Hudak A, Keeffe JR, Cosimi LA, Brown EM, Muecksch F, Weisblum Y, Zhang S, Delorey T, Woolley AE, Ghantous F, Park SM, Phillips D, Tusi B, Huey-Tubman KE, Cohen AA, Gnanapragasam PNP, Rzasa K, Hatziioanno T, Durney MA, Gu X, Tada T, Landau NR, West AP, Rozenblatt-Rosen O, Seaman MS, Baden LR, Graham DB, Deguine J, Bieniasz PD, Regev A, Hung D, Bjorkman PJ, Xavier RJ. Cell 184 3205-3221.e24 (2021)
  22. Characterization and structural basis of a lethal mouse-adapted SARS-CoV-2. Sun S, Gu H, Cao L, Chen Q, Ye Q, Yang G, Li RT, Fan H, Deng YQ, Song X, Qi Y, Li M, Lan J, Feng R, Guo Y, Zhu N, Qin S, Wang L, Zhang YF, Zhou C, Zhao L, Chen Y, Shen M, Cui Y, Yang X, Wang X, Tan W, Wang H, Wang X, Qin CF. Nat Commun 12 5654 (2021)
  23. Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters. Piepenbrink MS, Park JG, Oladunni FS, Deshpande A, Basu M, Sarkar S, Loos A, Woo J, Lovalenti P, Sloan D, Ye C, Chiem K, Bates CW, Burch RE, Erdmann NB, Goepfert PA, Truong VL, Walter MR, Martinez-Sobrido L, Kobie JJ. Cell Rep Med 2 100218 (2021)
  24. Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron. Cui Z, Liu P, Wang N, Wang L, Fan K, Zhu Q, Wang K, Chen R, Feng R, Jia Z, Yang M, Xu G, Zhu B, Fu W, Chu T, Feng L, Wang Y, Pei X, Yang P, Xie XS, Cao L, Cao Y, Wang X. Cell 185 860-871.e13 (2022)
  25. A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes. Guo Y, Huang L, Zhang G, Yao Y, Zhou H, Shen S, Shen B, Li B, Li X, Zhang Q, Chen M, Chen D, Wu J, Fu D, Zeng X, Feng M, Pi C, Wang Y, Zhou X, Lu M, Li Y, Fang Y, Lu YY, Hu X, Wang S, Zhang W, Gao G, Adrian F, Wang Q, Yu F, Peng Y, Gabibov AG, Min J, Wang Y, Huang H, Stepanov A, Zhang W, Cai Y, Liu J, Yuan Z, Zhang C, Lou Z, Deng F, Zhang H, Shan C, Schweizer L, Sun K, Rao Z. Nat Commun 12 2623 (2021)
  26. A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. Martinez DR, Schäfer A, Gobeil S, Li D, De la Cruz G, Parks R, Lu X, Barr M, Stalls V, Janowska K, Beaudoin E, Manne K, Mansouri K, Edwards RJ, Cronin K, Yount B, Anasti K, Montgomery SA, Tang J, Golding H, Shen S, Zhou T, Kwong PD, Graham BS, Mascola JR, Montefiori DC, Alam SM, Sempowski G, Sempowski GD, Khurana S, Wiehe K, Saunders KO, Acharya P, Haynes BF, Baric RS. Sci Transl Med 14 eabj7125 (2022)
  27. A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. Liu H, Yuan M, Huang D, Bangaru S, Zhao F, Lee CD, Peng L, Barman S, Zhu X, Nemazee D, Burton DR, van Gils MJ, Sanders RW, Kornau HC, Reincke SM, Prüss H, Kreye J, Wu NC, Ward AB, Wilson IA. Cell Host Microbe 29 806-818.e6 (2021)
  28. Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies: Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations. Verkhivker GM, Agajanian S, Oztas DY, Gupta G. Biochemistry 60 1459-1484 (2021)
  29. Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers. Rujas E, Kucharska I, Tan YZ, Benlekbir S, Cui H, Zhao T, Wasney GA, Budylowski P, Guvenc F, Newton JC, Sicard T, Semesi A, Muthuraman K, Nouanesengsy A, Aschner CB, Prieto K, Bueler SA, Youssef S, Liao-Chan S, Glanville J, Christie-Holmes N, Mubareka S, Gray-Owen SD, Rubinstein JL, Treanor B, Julien JP. Nat Commun 12 3661 (2021)
  30. Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies. Yan R, Wang R, Ju B, Yu J, Zhang Y, Liu N, Wang J, Zhang Q, Chen P, Zhou B, Li Y, Shen Y, Zhang S, Tian L, Guo Y, Xia L, Zhong X, Cheng L, Ge X, Zhao J, Wang HW, Wang X, Zhang Z, Zhang L, Zhou Q. Cell Res 31 517-525 (2021)
  31. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern. Deshpande A, Harris BD, Martinez-Sobrido L, Kobie JJ, Walter MR. Front Immunol 12 691715 (2021)
  32. Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2. Bojadzic D, Alcazar O, Chen J, Chuang ST, Condor Capcha JM, Shehadeh LA, Buchwald P. ACS Infect Dis 7 1519-1534 (2021)
  33. Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11. Fedry J, Hurdiss DL, Wang C, Li W, Obal G, Drulyte I, Du W, Howes SC, van Kuppeveld FJM, Förster F, Bosch BJ. Sci Adv 7 eabf5632 (2021)
  34. Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. Halwe S, Kupke A, Vanshylla K, Liberta F, Gruell H, Zehner M, Rohde C, Krähling V, Gellhorn Serra M, Kreer C, Klüver M, Sauerhering L, Schmidt J, Cai Z, Han F, Young D, Yang G, Widera M, Koch M, Werner A, Kämper L, Becker N, Marlow MS, Eickmann M, Ciesek S, Schiele F, Klein F, Becker S. Viruses 13 1498 (2021)
  35. Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope. Makdasi E, Levy Y, Alcalay R, Noy-Porat T, Zahavy E, Mechaly A, Epstein E, Peretz E, Cohen H, Bar-On L, Chitlaru T, Cohen O, Glinert I, Achdout H, Israely T, Rosenfeld R, Mazor O. Viruses 13 566 (2021)
  36. Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis. Zhang L, Zheng B, Gao X, Zhang L, Pan H, Qiao Y, Suo G, Zhu F. Front Immunol 11 595970 (2020)
  37. Letter Structure-based development of three- and four-antibody cocktails against SARS-CoV-2 via multiple mechanisms. Sun Y, Wang L, Feng R, Wang N, Wang Y, Zhu D, Xing X, Yang P, Zhang Y, Li W, Wang X. Cell Res 31 597-600 (2021)
  38. The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom. Wu J, Zhang L, Zhang Y, Wang H, Ding R, Nie J, Li Q, Liu S, Yu Y, Yang X, Duan K, Qu X, Wang Y, Huang W. Front Immunol 12 687869 (2021)
  39. A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2. Zhang L, Cao L, Gao XS, Zheng BY, Deng YQ, Li JX, Feng R, Bian Q, Guo XL, Wang N, Qiu HY, Wang L, Cui Z, Ye Q, Chen G, Lu KK, Chen Y, Chen YT, Pan HX, Yu J, Yao W, Zhu BL, Chen J, Liu Y, Qin CF, Wang X, Zhu FC. Natl Sci Rev 8 nwab053 (2021)
  40. Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy. Gupta Y, Maciorowski D, Zak SE, Kulkarni CV, Herbert AS, Durvasula R, Fareed J, Dye JM, Kempaiah P. Int J Biol Macromol 183 203-212 (2021)
  41. The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms. Paiardi G, Richter S, Oreste P, Urbinati C, Rusnati M, Wade RC. J Biol Chem 298 101507 (2022)
  42. A Trimeric Hydrophobic Zipper Mediates the Intramembrane Assembly of SARS-CoV-2 Spike. Fu Q, Chou JJ. J Am Chem Soc 143 8543-8546 (2021)
  43. Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2. Lim SA, Gramespacher JA, Pance K, Rettko NJ, Solomon P, Jin J, Lui I, Elledge SK, Liu J, Bracken CJ, Simmons G, Zhou XX, Leung KK, Wells JA. MAbs 13 1893426 (2021)
  44. Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants. Li T, Xue W, Zheng Q, Song S, Yang C, Xiong H, Zhang S, Hong M, Zhang Y, Yu H, Zhang Y, Sun H, Huang Y, Deng T, Chi X, Li J, Wang S, Zhou L, Chen T, Wang Y, Cheng T, Zhang T, Yuan Q, Zhao Q, Zhang J, McLellan JS, Zhou ZH, Zhang Z, Li S, Gu Y, Xia N. Nat Commun 12 5652 (2021)
  45. Design and Numerical Analysis of a Graphene-Coated SPR Biosensor for Rapid Detection of the Novel Coronavirus. Akib TBA, Mou SF, Rahman MM, Rana MM, Islam MR, Mehedi IM, Mahmud MAP, Kouzani AZ. Sensors (Basel) 21 3491 (2021)
  46. Inhalable nanocatchers for SARS-CoV-2 inhibition. Zhang H, Zhu W, Jin Q, Pan F, Zhu J, Liu Y, Chen L, Shen J, Yang Y, Chen Q, Liu Z. Proc Natl Acad Sci U S A 118 e2102957118 (2021)
  47. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants. Wang K, Jia Z, Bao L, Wang L, Cao L, Chi H, Hu Y, Li Q, Zhou Y, Jiang Y, Zhu Q, Deng Y, Liu P, Wang N, Wang L, Liu M, Li Y, Zhu B, Fan K, Fu W, Yang P, Pei X, Cui Z, Qin L, Ge P, Wu J, Liu S, Chen Y, Huang W, Wang Q, Qin CF, Wang Y, Qin C, Wang X. Nature 603 919-925 (2022)
  48. Synthesis and immunological evaluation of synthetic peptide based anti-SARS-CoV-2 vaccine candidates. Zhao Q, Gao Y, Xiao M, Huang X, Wu X. Chem Commun (Camb) 57 1474-1477 (2021)
  49. Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen. Srivastava V, Niu L, Phadke KS, Bellaire BH, Cho MW. Front Immunol 12 637982 (2021)
  50. Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants. Nie J, Xie J, Liu S, Wu J, Liu C, Li J, Liu Y, Wang M, Zhao H, Zhang Y, Yao J, Chen L, Shen Y, Yang Y, Wang HW, Wang Y, Huang W. Cell Discov 7 53 (2021)
  51. A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses. Wang P, Casner RG, Nair MS, Yu J, Guo Y, Wang M, Chan JF, Cerutti G, Iketani S, Liu L, Sheng Z, Chen Z, Yuen KY, Kwong PD, Huang Y, Shapiro L, Ho DD. Emerg Microbes Infect 11 147-157 (2022)
  52. A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. Yang Z, Wang Y, Jin Y, Zhu Y, Wu Y, Li C, Kong Y, Song W, Tian X, Zhan W, Huang A, Zhou S, Xia S, Tian X, Peng C, Chen C, Shi Y, Hu G, Du S, Wang Y, Xie Y, Jiang S, Lu L, Sun L, Song Y, Ying T. Signal Transduct Target Ther 6 378 (2021)
  53. Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2. Zhu L, Deng YQ, Zhang RR, Cui Z, Sun CY, Fan CF, Xing X, Huang W, Chen Q, Zhang NN, Ye Q, Cao TS, Wang N, Wang L, Cao L, Wang H, Kong D, Ma J, Luo C, Zhang Y, Nie J, Sun Y, Lv Z, Shaw N, Li Q, Li XF, Hu J, Xie L, Rao Z, Wang Y, Wang X, Qin CF. Natl Sci Rev 8 nwaa297 (2021)
  54. Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity. Zhou W, Xu C, Wang P, Anashkina AA, Jiang Q. Brief Bioinform 23 bbab375 (2022)
  55. Potent neutralization of SARS-CoV-2 including variants of concern by vaccines presenting the receptor-binding domain multivalently from nanoscaffolds. Halfmann PJ, Castro A, Loeffler K, Frey SJ, Chiba S, Kawaoka Y, Kane RS. Bioeng Transl Med 6 e10253 (2021)
  56. Tagged extracellular vesicles with the RBD of the viral spike protein for delivery of antiviral agents against SARS-COV-2 infection. Fu Y, Xiong S. J Control Release 335 584-595 (2021)
  57. An Antigenic Space Framework for Understanding Antibody Escape of SARS-CoV-2 Variants. Miller NL, Clark T, Raman R, Sasisekharan R. Viruses 13 2009 (2021)
  58. Conformational dynamics of the Beta and Kappa SARS-CoV-2 spike proteins and their complexes with ACE2 receptor revealed by cryo-EM. Wang Y, Xu C, Wang Y, Hong Q, Zhang C, Li Z, Xu S, Zuo Q, Liu C, Huang Z, Cong Y. Nat Commun 12 7345 (2021)
  59. Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen. Jiang M, Zhang G, Liu H, Ding P, Liu Y, Tian Y, Wang Y, Wang A. Front Immunol 12 707977 (2021)
  60. Inhaled ACE2-engineered microfluidic microsphere for intratracheal neutralization of COVID-19 and calming of the cytokine storm. Wang Z, Xiang L, Lin F, Cai Z, Ruan H, Wang J, Liang J, Wang F, Lu M, Cui W. Matter 5 336-362 (2022)
  61. Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries. Pan Y, Du J, Liu J, Wu H, Gui F, Zhang N, Deng X, Song G, Li Y, Lu J, Wu X, Zhan S, Jing Z, Wang J, Yang Y, Liu J, Chen Y, Chen Q, Zhang H, Hu H, Duan K, Wang M, Wang Q, Yang X. Cell Discov 7 57 (2021)
  62. Structural and energetic profiling of SARS-CoV-2 receptor binding domain antibody recognition and the impact of circulating variants. Yin R, Guest JD, Taherzadeh G, Gowthaman R, Mittra I, Quackenbush J, Pierce BG. PLoS Comput Biol 17 e1009380 (2021)
  63. Structure-guided antibody cocktail for prevention and treatment of COVID-19. Su SC, Yang TJ, Yu PY, Liang KH, Chen WY, Yang CW, Lin HT, Wang MJ, Lu RM, Tso HC, Chung MJ, Hsieh TY, Chang YL, Lin SC, Hsu FY, Ke FY, Wu YH, Hwang YC, Liu IJ, Liang JJ, Liao CC, Ko HY, Sun CP, Wu PY, Jan JT, Chang YC, Lin YL, Tao MH, Hsu SD, Wu HC. PLoS Pathog 17 e1009704 (2021)
  64. Egg yolk immunoglobulin (IgY) targeting SARS-CoV-2 S1 as potential virus entry blocker. Bao L, Zhang C, Lyu J, Yi P, Shen X, Tang B, Zhao H, Ren B, Kuang Y, Zhou L, Li Y. J Appl Microbiol 132 2421-2430 (2022)
  65. Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. Yuan M, Liu H, Wu NC, Wilson IA. Biochem Biophys Res Commun 538 192-203 (2021)
  66. Regional and temporal coordinated mutation patterns in SARS-CoV-2 spike protein revealed by a clustering and network analysis. Negi SS, Schein CH, Braun W. Sci Rep 12 1128 (2022)
  67. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer. Zhan W, Tian X, Zhang X, Xing S, Song W, Liu Q, Hao A, Hu Y, Zhang M, Ying T, Chen Z, Lan F, Sun L. J Virol 96 e0048022 (2022)
  68. All-Atom Simulations of Human ACE2-Spike Protein RBD Complexes for SARS-CoV-2 and Some of its Variants: Nature of Interactions and Free Energy Diagrams for Dissociation of the Protein Complexes. Dutta S, Panthi B, Chandra A. J Phys Chem B 126 5375-5389 (2022)
  69. Antibody cocktail effective against variants of SARS-CoV-2. Liang KH, Chiang PY, Ko SH, Chou YC, Lu RM, Lin HT, Chen WY, Lin YL, Tao MH, Jan JT, Wu HC. J Biomed Sci 28 80 (2021)
  70. Atomistic Simulations and In Silico Mutational Profiling of Protein Stability and Binding in the SARS-CoV-2 Spike Protein Complexes with Nanobodies: Molecular Determinants of Mutational Escape Mechanisms. Verkhivker GM, Agajanian S, Oztas DY, Gupta G. ACS Omega 6 26354-26371 (2021)
  71. Mechanical activation of spike fosters SARS-CoV-2 viral infection. Hu W, Zhang Y, Fei P, Zhang T, Yao D, Gao Y, Liu J, Chen H, Lu Q, Mudianto T, Zhang X, Xiao C, Ye Y, Sun Q, Zhang J, Xie Q, Wang PH, Wang J, Li Z, Lou J, Chen W. Cell Res 31 1047-1060 (2021)
  72. Point mutations in SARS-CoV-2 variants induce long-range dynamical perturbations in neutralizing antibodies. Ray D, Quijano RN, Andricioaei I. Chem Sci 13 7224-7239 (2022)
  73. Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies. Wang Y, Liu C, Zhang C, Wang Y, Hong Q, Xu S, Li Z, Yang Y, Huang Z, Cong Y. Nat Commun 13 871 (2022)
  74. Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD. Errico JM, Zhao H, Chen RE, Liu Z, Case JB, Ma M, Schmitz AJ, Rau MJ, Fitzpatrick JAJ, Shi PY, Diamond MS, Whelan SPJ, Ellebedy AH, Fremont DH. Cell Rep 109881 (2021)
  75. Targeting multiple epitopes on the spike protein: a new hope for COVID-19 antibody therapy. Sun Y, Kobe B, Qi J. Signal Transduct Target Ther 5 208 (2020)
  76. VarEPS: an evaluation and prewarning system of known and virtual variations of SARS-CoV-2 genomes. Sun Q, Shu C, Shi W, Luo Y, Fan G, Nie J, Bi Y, Wang Q, Qi J, Lu J, Zhou Y, Shen Z, Meng Z, Zhang X, Yu Z, Gao S, Wu L, Ma J, Hu S. Nucleic Acids Res 50 D888-D897 (2022)
  77. What are protective antibody responses to pandemic SARS-CoV-2? Henderson JP. J Clin Invest 130 6232-6234 (2020)
  78. Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant. Verkhivker G. Int J Mol Sci 23 2172 (2022)
  79. An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity. Borriello F, Poli V, Shrock E, Spreafico R, Liu X, Pishesha N, Carpenet C, Chou J, Di Gioia M, McGrath ME, Dillen CA, Barrett NA, Lacanfora L, Franco ME, Marongiu L, Iwakura Y, Pucci F, Kruppa MD, Ma Z, Lowman DW, Ensley HE, Nanishi E, Saito Y, O'Meara TR, Seo HS, Dhe-Paganon S, Dowling DJ, Frieman M, Elledge SJ, Levy O, Irvine DJ, Ploegh HL, Williams DL, Zanoni I. Cell 185 614-629.e21 (2022)
  80. Characterization of cross-reactive monoclonal antibodies against SARS-CoV-1 and SARS-CoV-2: Implication for rational design and development of pan-sarbecovirus vaccines and neutralizing antibodies. Li S, Wu J, Jiang W, He H, Zhou Y, Wu W, Gao Y, Xie M, Xia A, He J, Zhang Q, Han Y, Wang N, Zhu G, Wang Q, Zhang Z, Mayer CT, Wang K, Wang X, Wang J, Chen Z, Jiang S, Sun L, Xia R, Wang Q. J Med Virol 95 e28440 (2023)
  81. Computational Analysis of Mutations in the Receptor-Binding Domain of SARS-CoV-2 Spike and Their Effects on Antibody Binding. Bozdaganyan ME, Shaitan KV, Kirpichnikov MP, Sokolova OS, Orekhov PS. Viruses 14 295 (2022)
  82. Evaluation of SARS-CoV-2-Neutralizing Nanobody Using Virus Receptor Binding Domain-Administered Model Mice. Liu S, Li G, Ding L, Ding J, Zhang Q, Li D, Hou X, Kong X, Zou J, Zhang S, Han H, Wan Y, Yang Z, Zhu H. Research (Wash D C) 2022 9864089 (2022)
  83. Induction of Broadly Cross-Reactive Antibody Responses to SARS-CoV-2 Variants by S1 Nanoparticle Vaccines. Sun C, Yuan RY, Xie C, Sun JF, Fang XY, Hu YS, Yu XH, Liu Z, Zeng MS, Kang YF. J Virol 96 e0038322 (2022)
  84. Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. Ku Z, Xie X, Davidson E, Ye X, Su H, Menachery VD, Li Y, Yuan Z, Zhang X, Muruato AE, I Escuer AG, Tyrell B, Doolan K, Doranz BJ, Wrapp D, Bates PF, McLellan JS, Weiss SR, Zhang N, Shi PY, An Z. Nat Commun 12 469 (2021)
  85. Neutralizing antibodies targeting SARS-CoV-2 spike protein. Xiaojie S, Yu L, Lei Y, Guang Y, Min Q. Stem Cell Res 50 102125 (2020)
  86. Probing the Allosteric Inhibition Mechanism of a Spike Protein Using Molecular Dynamics Simulations and Active Compound Identifications. Wang Q, Wang L, Zhang Y, Zhang X, Zhang L, Shang W, Bai F. J Med Chem 65 2827-2835 (2022)
  87. Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection. Yao H, Sun Y, Deng YQ, Wang N, Tan Y, Zhang NN, Li XF, Kong C, Xu YP, Chen Q, Cao TS, Zhao H, Yan X, Cao L, Lv Z, Zhu D, Feng R, Wu N, Zhang W, Hu Y, Chen K, Zhang RR, Lv Q, Sun S, Zhou Y, Yan R, Yang G, Sun X, Liu C, Lu X, Cheng L, Qiu H, Huang XY, Weng T, Shi D, Jiang W, Shao J, Wang L, Zhang J, Jiang T, Lang G, Qin CF, Li L, Wang X. Cell Res 31 25-36 (2021)
  88. Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir. Peng Q, Peng R, Yuan B, Wang M, Zhao J, Fu L, Qi J, Shi Y. Innovation (N Y) 2 100080 (2021)
  89. Structural and functional analysis of an inter-Spike bivalent neutralizing antibody against SARS-CoV-2 variants. Li Y, Fan Q, Zhou B, Shen Y, Zhang Y, Cheng L, Qi F, Song S, Guo Y, Yan R, Ju B, Zhang Z. iScience 25 104431 (2022)
  90. Structural heterogeneity and precision of implications drawn from cryo-electron microscopy structures: SARS-CoV-2 spike-protein mutations as a test case. Mehra R, Kepp KP. Eur Biophys J 51 555-568 (2022)
  91. Letter The Infection and Pathogenicity of SARS-CoV-2 Variant B.1.351 in hACE2 Mice. Chen Q, Huang XY, Tian Y, Fan C, Sun M, Zhou C, Li R, Zhang RR, Wu G, Qin CF. Virol Sin 36 1232-1235 (2021)
  92. The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2. Xiong H, Sun H, Wang S, Yuan L, Liu L, Zhu Y, Zhang J, Huang Y, Qi R, Jiang Y, Ma J, Zhou M, Ma Y, Fu R, Yan S, Yue M, Wu Y, Wei M, Wang Y, Li T, Wang Y, Zheng Z, Yu H, Cheng T, Li S, Yuan Q, Zhang J, Guan Y, Zheng Q, Zhang T, Xia N. Proc Natl Acad Sci U S A 119 e2204256119 (2022)
  93. Uncovering a conserved vulnerability site in SARS-CoV-2 by a human antibody. Li T, Cai H, Zhao Y, Li Y, Lai Y, Yao H, Liu LD, Sun Z, van Vlissingen MF, Kuiken T, GeurtsvanKessel CH, Zhang N, Zhou B, Lu L, Gong Y, Qin W, Mondal M, Duan B, Xu S, Richard AS, Raoul H, Chen J, Xu C, Wu L, Zhou H, Huang Z, Zhang X, Li J, Wang Y, Bi Y, Rockx B, Chen J, Meng FL, Lavillette D, Li D. EMBO Mol Med 13 e14544 (2021)
  94. A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protection. Adams LJ, VanBlargan LA, Liu Z, Gilchuk P, Zhao H, Chen RE, Raju S, Chong Z, Whitener BM, Shrihari S, Jethva PN, Gross ML, Crowe JE, Whelan SPJ, Diamond MS, Fremont DH. Cell Rep Med 4 101305 (2023)
  95. A highly immunogenic live-attenuated vaccine candidate prevents SARS-CoV-2 infection and transmission in hamsters. Li XF, Cui Z, Fan H, Chen Q, Cao L, Qiu HY, Zhang NN, Xu YP, Zhang RR, Zhou C, Ye Q, Deng YQ, Guo Y, Qin S, Fan K, Wang L, Jia Z, Cui Y, Wang X, Qin CF. Innovation (Camb) 3 100221 (2022)
  96. A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD. Wang X, Hu A, Chen X, Zhang Y, Yu F, Yue S, Li A, Zhang J, Pan Z, Yang Y, Lin Y, Gao L, Zhou J, Zhao J, Li F, Shi Y, Huang F, Yang X, Peng Y, Tu L, Zhang H, Zheng H, He J, Zhang H, Xu L, Huang Q, Zhu Y, Deng K, Ye L. Signal Transduct Target Ther 7 114 (2022)
  97. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. Huang Q, Ji K, Tian S, Wang F, Huang B, Tong Z, Tan S, Hao J, Wang Q, Tan W, Gao GF, Yan J. Nat Commun 12 776 (2021)
  98. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Kim C, Ryu DK, Lee J, Kim YI, Seo JM, Kim YG, Jeong JH, Kim M, Kim JI, Kim P, Bae JS, Shim EY, Lee MS, Kim MS, Noh H, Park GS, Park JS, Son D, An Y, Lee JN, Kwon KS, Lee JY, Lee H, Yang JS, Kim KC, Kim SS, Woo HM, Kim JW, Park MS, Yu KM, Kim SM, Kim EH, Park SJ, Jeong ST, Yu CH, Song Y, Gu SH, Oh H, Koo BS, Hong JJ, Ryu CM, Park WB, Oh MD, Choi YK, Lee SY. Nat Commun 12 288 (2021)
  99. Biopanning of specific peptide for SARS-CoV-2 nucleocapsid protein and enzyme-linked immunosorbent assay-based antigen assay. Ma P, Liu J, Pang S, Zhou W, Yu H, Wang M, Dong T, Wang Y, Wang Q, Liu A. Anal Chim Acta 1264 341300 (2023)
  100. Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD. Ma H, Guo Y, Tang H, Tseng CK, Wang L, Zong H, Wang Z, He Y, Chang Y, Wang S, Huang H, Ke Y, Yuan Y, Wu M, Zhang Y, Drelich A, Kempaiah KR, Peng BH, Wang A, Yang K, Yin H, Liu J, Yue Y, Xu W, Zhu S, Ji T, Zhang X, Wang Z, Li G, Liu G, Song J, Mu L, Xiang Z, Song Z, Chen H, Bian Y, Zhang B, Chen H, Zhang J, Liao Y, Zhang L, Yang L, Chen Y, Gilly J, Xiao X, Han L, Jiang H, Xie Y, Zhou Q, Zhu J. Cell Discov 8 16 (2022)
  101. Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses. Li M, Ren Y, Aw ZQ, Chen B, Yang Z, Lei Y, Cheng L, Liang Q, Hong J, Yang Y, Chen J, Wong YH, Wei J, Shan S, Zhang S, Ge J, Wang R, Dong JZ, Chen Y, Shi X, Zhang Q, Zhang Z, Chu JJH, Wang X, Zhang L. Nat Commun 13 7957 (2022)
  102. Characterization of a SARS-CoV-2 spike protein reference material. Stocks BB, Thibeault MP, Schrag JD, Melanson JE. Anal Bioanal Chem 414 3561-3569 (2022)
  103. Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex. Tada M, Aoyama M, Ishii-Watabe A. MAbs 15 2222874 (2023)
  104. Collaborative effects of 2019-nCoV-Spike mutants on viral infectivity. Fang S, Lei C, Li M, Ming Y, Liu L, Zhou X, Li M. Comput Struct Biotechnol J 21 5125-5135 (2023)
  105. Computational Insights into the Allosteric Effect and Dynamic Structural Features of the SARS-COV-2 Spike Protein. Xue Q, Liu X, Pan W, Zhang A, Fu J, Jiang G. Chemistry 28 e202104215 (2022)
  106. Computational Insights into the Conformational Accessibility and Binding Strength of SARS-CoV-2 Spike Protein to Human Angiotensin-Converting Enzyme 2. Peng C, Zhu Z, Shi Y, Wang X, Mu K, Yang Y, Zhang X, Xu Z, Zhu W. J Phys Chem Lett 11 10482-10488 (2020)
  107. Computational approach for binding prediction of SARS-CoV-2 with neutralizing antibodies. Beshnova D, Fang Y, Du M, Sun Y, Du F, Ye J, Chen ZJ, Li B. Comput Struct Biotechnol J 20 2212-2222 (2022)
  108. Computer Simulations and Network-Based Profiling of Binding and Allosteric Interactions of SARS-CoV-2 Spike Variant Complexes and the Host Receptor: Dissecting the Mechanistic Effects of the Delta and Omicron Mutations. Verkhivker G, Agajanian S, Kassab R, Krishnan K. Int J Mol Sci 23 4376 (2022)
  109. Conformational Dynamics of the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein. Mamchur AA, Stanishneva-Konovalova TB, Mokrushina YA, Abrikosova VA, Guo Y, Zhang H, Terekhov SS, Smirnov IV, Yaroshevich IA. Biomedicines 10 3233 (2022)
  110. Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response. Dickey TH, Tang WK, Butler B, Ouahes T, Orr-Gonzalez S, Salinas ND, Lambert LE, Tolia NH. Sci Adv 8 eabq8276 (2022)
  111. Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. Zhang C, Wang Y, Zhu Y, Liu C, Gu C, Xu S, Wang Y, Zhou Y, Wang Y, Han W, Hong X, Yang Y, Zhang X, Wang T, Xu C, Hong Q, Wang S, Zhao Q, Qiao W, Zang J, Kong L, Wang F, Wang H, Qu D, Lavillette D, Tang H, Deng Q, Xie Y, Cong Y, Huang Z. Nat Commun 12 264 (2021)
  112. Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method. Dou Y, Xu K, Deng YQ, Jia Z, Lan J, Xu X, Zhang G, Cao T, Liu P, Wang X, Wang X, Xu L, Du P, Qin CF, Liu H, Li Y, Wu G, Wang K, Lu B. Antib Ther 6 76-86 (2023)
  113. Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients. Guo Y, Li T, Xia X, Su B, Li H, Feng Y, Han J, Wang X, Jia L, Bao Z, Li J, Liu Y, Li L. Front Immunol 12 723585 (2021)
  114. Disulfide stabilization reveals conserved dynamic features between SARS-CoV-1 and SARS-CoV-2 spikes. Zhang X, Li Z, Zhang Y, Liu Y, Wang J, Liu B, Chen Q, Wang Q, Fu L, Wang P, Zhong X, Jin L, Yan Q, Chen L, He J, Zhao J, Xiong X. Life Sci Alliance 6 e202201796 (2023)
  115. Engineering recombinantly expressed lectin-based antiviral agents. Maier I. Front Cell Infect Microbiol 12 990875 (2022)
  116. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Zhou Y, Liu Z, Li S, Xu W, Zhang Q, Silva IT, Li C, Wu Y, Jiang Q, Liu Z, Wang Q, Guo Y, Wu J, Gu C, Cai X, Qu D, Mayer CT, Wang X, Jiang S, Ying T, Yuan Z, Xie Y, Wen Y, Lu L, Wang Q. Cell Rep 34 108699 (2021)
  117. Functional Peptides from SARS-CoV-2 Binding with Cell Membrane: From Molecular Dynamics Simulations to Cell Demonstration. Hao Y, Wu R, Wang F, Zhang L, Wang Z, Song X, Liu L. Cells 11 1738 (2022)
  118. Host susceptibility and structural and immunological insight of S proteins of two SARS-CoV-2 closely related bat coronaviruses. Ou X, Xu G, Li P, Liu Y, Zan F, Liu P, Hu J, Lu X, Dong S, Zhou Y, Mu Z, Wu Z, Wang J, Jin Q, Liu P, Lu J, Wang X, Qian Z. Cell Discov 9 78 (2023)
  119. Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein. Bordoloi D, Xu Z, Ho M, Purwar M, Bhojnagarwala P, Cassel J, Giron LB, Walker S, Kulkarni AJ, Ruiz ET, Choi J, Zaidi FI, Wu Y, Wang S, Patel A, Ramos S, Smith T, Kulp D, Ugen KE, Srinivasan A, Abdel-Mohsen M, Humeau L, Weiner DB, Muthumani K. ACS Pharmacol Transl Sci 4 1349-1361 (2021)
  120. Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model. Mohandas S, Yadav PD, Shete-Aich A, Abraham P, Vadrevu KM, Sapkal G, Mote C, Nyayanit D, Gupta N, Srinivas VK, Kadam M, Kumar A, Majumdar T, Jain R, Deshpande G, Patil S, Sarkale P, Patil D, Ella R, Prasad SD, Sharma S, Ella KM, Panda S, Bhargava B. iScience 24 102054 (2021)
  121. In silico analysis suggests less effective MHC-II presentation of SARS-CoV-2 RBM peptides: Implication for neutralizing antibody responses. Castro A, Ozturk K, Zanetti M, Carter H. PLoS One 16 e0246731 (2021)
  122. Innate Immune Response in SARS-CoV-2 Infection. Schiuma G, Beltrami S, Bortolotti D, Rizzo S, Rizzo R. Microorganisms 10 501 (2022)
  123. Ionization of D571 Is Coupled with SARS-CoV-2 Spike Up/Down Equilibrium Revealing the pH-Dependent Allosteric Mechanism of Receptor-Binding Domains. Li T, Yu L, Sun J, Liu J, He X. J Phys Chem B 126 4828-4839 (2022)
  124. Label-Free Analysis of Binding and Inhibition of SARS-Cov-19 Spike Proteins to ACE2 Receptor with ACE2-Derived Peptides by Surface Plasmon Resonance. Abouhajar F, Chaudhuri R, Valiulis SN, Stuart DD, Malinick AS, Xue M, Cheng Q. ACS Appl Bio Mater 6 182-190 (2023)
  125. Mapping the intersection of nanotechnology and SARS-CoV-2/COVID-19: A bibliometric analysis. Zhang X, Guo M, Huang Z, Huang Y, Wu C, Pan X. Infect Med (Beijing) 1 103-112 (2022)
  126. Modeling coronavirus spike protein dynamics: implications for immunogenicity and immune escape. Kunkel G, Madani M, White SJ, Verardi PH, Tarakanova A. Biophys J 120 5592-5618 (2021)
  127. Molecular Characterization and Selection of Indigenous SARS-CoV-2 Delta Variant for the Development of the First Inactivated SARS-CoV-2 Vaccine of Pakistan. Aziz MW, Mukhtar N, Anjum AA, Mushtaq MH, Shahid MF, Ali M, Shabbir MAB, Ali MA, Nawaz M, Yaqub T. Vaccines (Basel) 11 607 (2023)
  128. MutCov: A pipeline for evaluating the effect of mutations in spike protein on infectivity and antigenicity of SARS-CoV-2. Zhou W, Xu C, Luo M, Wang P, Xu Z, Xue G, Jin X, Huang Y, Li Y, Nie H, Jiang Q, Anashkina AA. Comput Biol Med 145 105509 (2022)
  129. Novel Polymyxin-Inspired Peptidomimetics Targeting the SARS-CoV-2 Spike:hACE2 Interface. Bugatti K, Sartori A, Battistini L, Coppa C, Vanhulle E, Noppen S, Provinciael B, Naesens L, Stevaert A, Contini A, Vermeire K, Zanardi F. Int J Mol Sci 24 8765 (2023)
  130. Novel neutralizing chicken IgY antibodies targeting 17 potent conserved peptides identified by SARS-CoV-2 proteome microarray, and future prospects. Li J, Liang T, Hei A, Wang X, Li H, Yu X, Zhao R, Gao P, Fang C, Zhou J, Li M, He E, Skog S. Front Immunol 13 1074077 (2022)
  131. Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses. Wang Y, Liu M, Shen Y, Ma Y, Li X, Zhang Y, Liu M, Yang XL, Chen J, Yan R, Luan D, Wang Y, Chen Y, Wang Q, Lin H, Li Y, Wu K, Zhu T, Zhao J, Lu H, Wen Y, Jiang S, Wu F, Zhou Q, Shi ZL, Huang J. Cell Discov 8 36 (2022)
  132. Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination. Ju B, Fan Q, Liu C, Shen S, Wang M, Guo H, Zhou B, Ge X, Zhang Z. Cell Rep 42 112532 (2023)
  133. Pathogen-host adhesion between SARS-CoV-2 spike proteins from different variants and human ACE2 studied at single-molecule and single-cell levels. Zhang X, Hong B, Wei P, Pei P, Xu H, Chen L, Tong Y, Chen J, Luo SZ, Fan H, He C. Emerg Microbes Infect 11 2658-2669 (2022)
  134. Potent and broad neutralization of SARS-CoV-2 variants of concern (VOCs) including omicron sub-lineages BA.1 and BA.2 by biparatopic human VH domains. Chen C, Saville JW, Marti MM, Schäfer A, Cheng MH, Mannar D, Zhu X, Berezuk AM, Banerjee A, Sobolewski MD, Kim A, Treat BR, Da Silva Castanha PM, Enick N, McCormick KD, Liu X, Adams C, Hines MG, Sun Z, Chen W, Jacobs JL, Barratt-Boyes SM, Mellors JW, Baric RS, Bahar I, Dimitrov DS, Subramaniam S, Martinez DR, Li W. iScience 25 104798 (2022)
  135. Prefusion spike protein conformational changes are slower in SARS-CoV-2 than in SARS-CoV-1. Govind Kumar V, Ogden DS, Isu UH, Polasa A, Losey J, Moradi M. J Biol Chem 298 101814 (2022)
  136. Recombinant VLPs empower RBM peptides showing no immunogenicity in native SARS-COV-2 protein to elicit a robust neutralizing antibody response. Long Q, Yang Y, Yang M, Bai H, Sun W, Yang X, Huang W, Li D, Ma Y. Nanomedicine 41 102527 (2022)
  137. SARS-CoV-2 spike HexaPro formulated in aluminium hydroxide and administered in an accelerated vaccination schedule partially protects Syrian Hamsters against viral challenge despite low neutralizing antibody responses. Christensen D, Polacek C, Sheward DJ, Hanke L, McInerney G, Murrell B, Hartmann KT, Jensen HE, Zimmermann J, Jungersen G, Illigen KE, Isling LK, Fernandez-Antunez C, Ramirez S, Bukh J, Pedersen GK. Front Immunol 14 941281 (2023)
  138. SARS-CoV-2 spike protein receptor-binding domain perturbates intracellular calcium homeostasis and impairs pulmonary vascular endothelial cells. Yang K, Liu S, Yan H, Lu W, Shan X, Chen H, Bao C, Feng H, Liao J, Liang S, Xu L, Tang H, Yuan JX, Zhong N, Wang J. Signal Transduct Target Ther 8 276 (2023)
  139. Stability and expression of SARS-CoV-2 spike-protein mutations. Bæk KT, Mehra R, Kepp KP. Mol Cell Biochem 478 1269-1280 (2023)
  140. Structural basis of nanobodies neutralizing SARS-CoV-2 variants. Shi Z, Li X, Wang L, Sun Z, Zhang H, Chen X, Cui Q, Qiao H, Lan Z, Zhang X, Li X, Li L, Xu J, Gong R, Fan C, Geng Y. Structure 30 707-720.e5 (2022)
  141. Letter Structure-based development of human antibody cocktails against SARS-CoV-2. Wang N, Sun Y, Feng R, Wang Y, Guo Y, Zhang L, Deng YQ, Wang L, Cui Z, Cao L, Zhang YJ, Li W, Zhu FC, Qin CF, Wang X. Cell Res 31 101-103 (2021)
  142. Structure-selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern. Almanza G, Clark AE, Kouznetsova V, Olmedillas E, Castro A, Tsigelny IF, Wu Y, Gao GF, Leibel SL, Bray W, Ollmann Saphire E, Carlin AF, Zanetti M. PLoS Pathog 18 e1010686 (2022)
  143. Suppression of ACE2 SUMOylation protects against SARS-CoV-2 infection through TOLLIP-mediated selective autophagy. Jin S, He X, Ma L, Zhuang Z, Wang Y, Lin M, Cai S, Wei L, Wang Z, Zhao Z, Wu Y, Sun L, Li C, Xie W, Zhao Y, Songyang Z, Peng K, Zhao J, Cui J. Nat Commun 13 5204 (2022)
  144. The diversity of the glycan shield of sarbecoviruses related to SARS-CoV-2. Allen JD, Ivory DP, Song SG, He WT, Capozzola T, Yong P, Burton DR, Andrabi R, Crispin M. Cell Rep 42 112307 (2023)
  145. The smallest functional antibody fragment: Ultralong CDR H3 antibody knob regions potently neutralize SARS-CoV-2. Huang R, Warner Jenkins G, Kim Y, Stanfield RL, Singh A, Martinez-Yamout M, Kroon GJ, Torres JL, Jackson AM, Kelley A, Shaabani N, Zeng B, Bacica M, Chen W, Warner C, Radoicic J, Joh J, Dinali Perera K, Sang H, Kim T, Yao J, Zhao F, Sok D, Burton DR, Allen J, Harriman W, Mwangi W, Chung D, Teijaro JR, Ward AB, Dyson HJ, Wright PE, Wilson IA, Chang KO, McGregor D, Smider VV. Proc Natl Acad Sci U S A 120 e2303455120 (2023)
  146. Unmethylated CpG motif-containing genomic DNA fragments of bacillus calmette-guerin improves immune response towards a DNA vaccine for COVID-19. Zhou Z, Zhang X, Li Q, Fu L, Wang M, Liu S, Wu J, Nie J, Zhang L, Zhao C, Jiang F, An Y, Yu B, Zheng H, Wang Y, Zhao A, Huang W. Vaccine 39 6050-6056 (2021)


Quick links